Searched for
ARV BUSINESS
Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upsideNuvama Institutional Equities has initiated coverage on Laurus Labs with a ‘Buy’ rating and a target price of Rs 2,520, implying a 24% upsi...- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsThe next few weeks are critical, and one should not be in a hurry to make market-related decisions. Better to be cautious – to wait and wat...
- Long-term investing is about looking beyond narratives, including AI: 5 large-caps with an upside potential of up to 24%As we see a recovery in the market, it is good to be cognizant of the fact that more than the narratives on the street, it is the earnings ...
- 5 stocks with consistent score improvement and upside potential of up to 34% in 1 year, according to analystsGiven the current global and domestic situation, the chances are that the volatility quotient in the market will remain high. So, the best ...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
- Short-term headwind? Yes. But the structure stays intact: 5 large-cap stocks with upside potential of up to 19%Wise men on the street will tell you it is foolish to try and time the market. And attempting to do so in the midst of a raging war is prob...
- Laurus Labs shares nosedive 15% amid reports of US foreign aid suspensionLaurus Labs reported a 7% YoY drop in API revenues to Rs 531 crore for Q3 FY24, driven by lower ARV volumes. However, the FDF segment saw A...
- Q1 Results Today: Laurus Labs, IEX and ACCLaurus Labs Q1 consolidated net profit fell 90% YoY to INR25 crore due to lower sales and elevated expenses. The API business reported a 2%...
- Prices can’t go down further in APIs or it will turn unviable for new entrants: Laurus Labs CEO“If you look at the current nine months financials, the ARV APIs and formulation put together contributed only 35% of revenue came from ARV...
- 3 reasons Laurus Labs is this week's stock pickLaurus Labs will benefit from the growth prospects of the global and domestic pharma indutry as spending on medicines, including Covid-19 v...
- Laurus Labs net profit rises 15% to Rs 233 crore in Q2FY23The company had reported a net profit of Rs 202 crore during the same period of the previous year. On a quarter-on-quarter (QoQ) basis , th...
- Laurus Labs Q3 results: Net profit drops 44% YoY to Rs 154 croreThe earnings before interest, tax, depreciation and amortization (EBITDA) decreased 17% YoY to Rs 290 crore. The EBITDA margins dropped by ...
- Buy Laurus Lab, target price Rs 623: AmbitThere is high medium-term growth visibility and R&D spend commercialization would drive FY22 P/E re-rating from 13 times to 18 times on the...
- Buy Laurus Labs, target Rs 535: HDFC SecuritiesBuy Laurus Labs at a price target of Rs 535.
- Buy Laurus Labs, target Rs 470: Motilal Oswal SecuritiesBuy Laurus Labs at a price target of Rs 470.
- Buy Laurus Labs, target Rs 480: HDFC SecuritiesBuy Laurus Labs at a price target of Rs 480.
- Lauras Labs’ Q2 net up 1% on higher capexFor the quarter ended September 2017, the company posted a 4.3% growth in its revenues to Rs 538.6 crore as against Rs 516.5 crore in the c...
- Sun Pharma may shed part of Ranbaxy business to push growthFaced with disappointing revenue and profit going forward, Sun Pharma is mulling options of exiting Ranbaxy's "low-margin" overseas geograp...
- Sun Pharma may exit part of Ranbaxy business to push growthExiting the low-margin businesses may not result in a huge cash flow, but will improve the profitability of the company.
- Indian firm sues South Africa after losing AIDS drug contractAn Indian manufacturer of drugs to treat HIV/AIDS is suing the South African government after failing to clinch a $400-million tender, Sout...
Load More
